JIANG, CHUNBO – Trademark Portfolio

Entity Type: 01

JIANG, CHUNBO holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include OEQ and GELAMI. The owner is based in BEIJING.

NO. 910, 11TH FLOOR, COURTYARD 1

FENGGUAN ROAD, FENGTAI DISTRICT

BEIJING 100071 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

OEQ
OEQ
Registered 2020
GELAMI
GELAMI
Registered 2020

Trademark Classifications

JIANG, CHUNBO's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (1 filing)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does JIANG, CHUNBO have?

JIANG, CHUNBO has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does JIANG, CHUNBO file in?

JIANG, CHUNBO files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What are JIANG, CHUNBO's most well-known trademarks?

JIANG, CHUNBO's registered trademark portfolio includes well-known marks such as OEQ and GELAMI. These are among 2 currently registered trademarks in the portfolio.

What is JIANG, CHUNBO's trademark registration success rate?

JIANG, CHUNBO has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.